SCHEMBL7449229

SCHEMBL7449229

NC(=CNCc1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.52
ADH1C P00326 1/20 0.52
ADH1A P07327 1/20 0.52
ADH7 P40394 1/20 0.52
CYP2C9 P11712 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 4/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
IDO1 P14902 2/20 0.42
THRB P10828 1/20 0.42
GAA P10253 1/20 0.42
MMP1 P03956 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7449222 1.00 ADH1B (0.52) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL20344487 0.89 ADH1B (0.52) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL20344664 0.83 ADH1B (0.46) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL19255773 0.79 SMN1; SMN2 (0.48) ADH1BADH1CADH1AADH7CYP2C19
SCHEMBL23188878 0.78 ADH1B (0.41) ADH1BADH1CADH1AADH7TSHR
SCHEMBL23188929 0.78 ADH1B (0.57) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL26983698 0.78 CYP2C9 (0.60) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL20344648 0.76 ADH1B (0.46) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL23620721 0.75 ADH1B (0.48) ADH1BADH1CADH1AADH7CYP2C9
SCHEMBL12631384 0.75 L3MBTL1 (0.50) ALDH1A1LMNAMAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6468977-B1 COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS APOTEX INC. (CA) 2002-10-22 US disclosed
WO-2001090095-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2001-11-29 WO disclosed